FMED

FMED seeks long-term capital appreciation by utilizing proprietary disruptive strategies in identifying companies involved in disruptive technologies for its portfolio. Disruptive technologies are innovations that may reshape how businesses currently deliver their services and operate, potentially displacing industry leaders over time. The fund primarily invests in growth and value stocks of companies tied with disruptive innovation in health care globally. These are organizations that deal with robotic surgery, cell and gene therapy, genomics, rare diseases, medical devices and equipment, immunotherapy, technology-based health care platforms, advanced diagnostics and consumer wellness. The fund adviser uses fundamental analysis, looking into an issuer's financial situation amongst other things, as well as economic and market conditions for its portfolio construction. The adviser may buy, sell and hold decisions at their discretion. FMED converted from a mutual fund to an actively managed ETF, with $44 million in assets.